Resultados de la búsqueda 31-40 of 4292 for Two-phase

1. Oncología (médica) - Ensayos clínicos - Mayo Clinic

   The objectives of this study are to determine the Maximum Tolerated Dose (MTD) and the Recommended Phase ... The study will be performed in two phases: Phase I ...

2. Clínica de las mamas - Ensayos clínicos - Mayo Clinic

   ... two parts - an initial "3 + 3" dose escalation phase (Part 1) with Sub-Parts 1A (monotherapy SAR444881), 1B (SAR444881 in combination with pembrolizumab) ...

3. Ensayos clínicos - Centro Pediátrico de Mayo Clinic

   The purpose of this two-part Phase 2 study is to assess the safety, tolerability and efficacy of aerosolized SF-RI 1 (AeroFact) when delivered via nCPAP at two ...

4. Ensayos clínicos - Centro Pediátrico de Mayo Clinic - Centro Pediátrico de Mayo Clinic

   The purpose of this two-part Phase 2 study is to assess the safety, tolerability and efficacy of aerosolized SF-RI 1 (AeroFact) when delivered via nCPAP at two ...

5. Clínica de las mamas - Ensayos clínicos - Mayo Clinic

   ... two parts - an initial "3 + 3" dose escalation phase (Part 1) with Sub-Parts 1A (monotherapy SAR444881), 1B (SAR444881 in combination with pembrolizumab) ...

6. Ensayos clínicos - Centro Pediátrico de Mayo Clinic - Centro Pediátrico de Mayo Clinic

   The purpose of this two-part Phase 2 study is to assess the safety, tolerability and efficacy of aerosolized SF-RI 1 (AeroFact) when delivered via nCPAP at two ...

7. Oncología (médica) - Ensayos clínicos

   The study will be performed in two phases: Phase I will be performed for ... Note: Mayo Clinic is only participating in the Phase 2 - Cohort 3 (UPLIFT) portion of ...

8. Ensayos clínicos - Centro Pediátrico de Mayo Clinic - Centro Pediátrico de Mayo Clinic

   The purpose of this two-part Phase 2 study is to assess the safety, tolerability and efficacy of aerosolized SF-RI 1 (AeroFact) when delivered via nCPAP at two ...

9. Clínica de las mamas - Ensayos clínicos - Mayo Clinic

   ... two parts - an initial "3 + 3" dose escalation phase (Part 1) with Sub-Parts 1A (monotherapy SAR444881), 1B (SAR444881 in combination with pembrolizumab) ...

10. Clínica de las mamas - Ensayos clínicos - Mayo Clinic

    ... two parts - an initial "3 + 3" dose escalation phase (Part 1) with Sub-Parts 1A (monotherapy SAR444881), 1B (SAR444881 in combination with pembrolizumab) ...